We read with interest the comment on our recent article regarding the follow-up of C-GBS and NC-GBS in the COVID-19 era.1 We fully agree with the reader’s observations, the majority of which were reported in our paper as limitations. In fact, due to the nature of the study (a single-center observation/case series) and for the small number and heterogeneity of the sample, it was not possible to conduct a statistical analysis; a descriptive analysis was performed, and each case was described with its functional follow-up. The high percentage of acute motor axonal neuropathy in our cohort, which is known to have a worse outcome than acute inflammatory demyelinating polyradiculopathy, probably was the most important factor that negatively influenced the recovery of those individuals, in association with the high rate of complications, as stated in our paper. We are aware that a preexisting peripheral nerve involvement or damage could represent a negative factor for the recovery, although none of our patients had documented neuropathy before the acute event.